clinical trial · NCT04578613
ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL
Beijing InnoCare Pharma Tech Co., Ltd.·phase3·unknown·n = 218
Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaICP-022ChlorambucilRituximab
brief summary
This is a randomized, multicenter, open-label, Phase 3 study to evaluate the efficacy and safety of ICP-022 versus Chlorambucil plus Rituximab in subjects with Previously Untreated Chronic Lymphocytic Leukemia.
started
Jan 8, 2021
primary completion
Dec 30, 2024
completion
Jun 30, 2025
last updated
Jun 5, 2023
official title
A Randomized, Controlled, Open, Multicenter Phase 3 Study to Evaluate ICP-022 Versus Chlorambucil Combined With Rituximab for Primary Treatment of Chronic Lymphocytic Leukemia(CLL)/ Small Lymphocytic Lymphoma(SLL)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol